Dacarbazine 600mg powder for solution for infusion vials
An antineoplastic agent.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Dacarbazine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Dacarbazine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
43.3 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(13)
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Tebentafusp for treating advanced uveal melanoma (TA1027)
Melanoma: assessment and management (NG14)
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 24 · 1984–2022
Showing the 50 most relevant studies, sorted by most relevant.
Nicolasine D. Niemeijer, Gabrielle Alblas, Leonie T. van Hulsteijn, et al.
Clinical Endocrinology, 2014
- Adrenal Gland Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Catecholamines
Patrick Schöffski, Sant P. Chawla, Robert G. Maki, et al.
The Lancet, 2016
- Polyether Polyketides
- Antineoplastic Agents
- Dacarbazine
Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, et al.
The Lancet Oncology, 2017
- Antineoplastic Combined Chemotherapy Protocols
- Benzimidazoles
- Dacarbazine
Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn, et al.
Journal of Clinical Oncology, 2018
- Progression-Free Survival
- Uveal Melanoma
- Antineoplastic Combined Chemotherapy Protocols
George D. Demetri, Margaret von Mehren, Robin L. Jones, et al.
Journal of Clinical Oncology, 2015
- Trabectedin
- Dacarbazine
- Dioxoles
Paul B. Chapman, Lawrence H. Einhorn, Michael L. Meyers, et al.
Journal of Clinical Oncology, 1999
- Antineoplastic Combined Chemotherapy Protocols
- Carmustine
- Cisplatin
D. Schadendorf, Selma Ugurel, B. Schuler-Thurner, et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 2006
- Dacarbazine
- Dendritic Cells
- Melanoma
Steven A. Rosenberg, James Chih‐Hsin Yang, Douglas J. Schwartzentruber, et al.
Journal of Clinical Oncology, 1999
- Interferon alpha-2
- Antineoplastic Combined Chemotherapy Protocols
- Cisplatin
David J. Straus, Carol S. Portlock, Jing Qin, et al.
Blood, 2004
- Antineoplastic Combined Chemotherapy Protocols
- Bleomycin
- Combined Modality Therapy
Karolin Behringer, Helen Goergen, Felicitas Hitz, et al.
The Lancet, 2014
- Antineoplastic Combined Chemotherapy Protocols
- Bleomycin
- Dacarbazine
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
5 hours
Mechanism
The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent.
Food interactions
1 warning
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
5 hours
Protein binding
5%
Metabolism
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1368 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:9705292
During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, an accessory subunit POLA2 and two primase subunits, the catalytic subunit PRIM1 and the regulatory subunit PRIM2) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1 (By similarity). The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands (By similarity). These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01AX04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Dacarbazine
Additional database identifiers
Drugs Product Database (DPD)
2264
ChemSpider
10481959
BindingDB
50238687
ZINC
ZINC000100019007
HUGO Gene Nomenclature Committee (HGNC)
HGNC:30073
GenAtlas
POLA2
GeneCards
POLA2
GenBank Gene Database
L24559
GenBank Protein Database
439601
UniProt Accession
DPOA2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8891
GeneCards
PGD
GenBank Gene Database
U30255
GenBank Protein Database
984325
UniProt Accession
6PGD_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2595
GeneCards
CYP1A1
GenBank Gene Database
K03191
GenBank Protein Database
181276
Guide to Pharmacology
1318
UniProt Accession
CP1A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2631
GeneCards
CYP2E1
GenBank Gene Database
J02625
GenBank Protein Database
181360
Guide to Pharmacology
1330
UniProt Accession
CP2E1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q416975), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.